Icosapent Ethyl
Brand name: Vascepa
Rank #54 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$334.9M
Total Cost
692,252
Total Claims
$334.9M
Total Cost
16,235
Prescribers
$484
Cost per Claim
96,633
Beneficiaries
1,083,935
30-Day Fills
$21K
Avg Cost/Provider
43
Avg Claims/Provider
Share of Medicare Part D Spending
0.12%
of total Medicare Part D spending
$334.9M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $334.9M total
Top Prescribers of Icosapent Ethyl
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Xiandong Shi | Internal Medicine | Flushing, NY | 3,141 | $1.4M |
| 2 | Xiaoqin Yin | Family Practice | Flushing, NY | 3,227 | $1.3M |
| 3 | Wuhua Jing | Internal Medicine | New York, NY | 1,327 | $1.3M |
| 4 | Chang Lee | Internal Medicine | Flushing, NY | 3,188 | $1.2M |
| 5 | Yong Yu | Internal Medicine | Flushing, NY | 1,820 | $1.2M |
| 6 | Xiangsheng Zheng | Internal Medicine | Birmingham, AL | 2,905 | $1.2M |
| 7 | Joo Jang | Nurse Practitioner | Leonia, NJ | 2,449 | $1.2M |
| 8 | Wei Lin | Internal Medicine | New York, NY | 2,284 | $1.1M |
| 9 | Gary Reznik | Cardiology | Los Angeles, CA | 2,512 | $1.0M |
| 10 | Zova Liu | Internal Medicine | Flushing, NY | 1,803 | $995K |
| 11 | Sang Baik | Internal Medicine | Los Angeles, CA | 2,135 | $954K |
| 12 | Joann Nguyen | Family Practice | San Jose, CA | 2,156 | $939K |
| 13 | Afshine Emrani | Cardiology | Tarzana, CA | 2,010 | $935K |
| 14 | Yili Huang | Cardiology | Elmhurst, NY | 1,193 | $908K |
| 15 | Yin Win | Internal Medicine | New York, NY | 1,003 | $864K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 51 | Secukinumab (Cosentyx Sensoready (2 Pens)) | $347.7M | 45,496 |
| 52 | Upadacitinib (Rinvoq) | $346.0M | 51,469 |
| 53 | Abiraterone Acetate (Abiraterone Acetate) | $345.0M | 122,643 |
| 54 | Icosapent Ethyl (Vascepa) | $334.9M | 692,252 |
| 55 | Cariprazine Hcl (Vraylar) | $329.1M | 226,854 |
| 56 | Albuterol Sulfate (Albuterol Sulfate Hfa) | $312.2M | 7,904,120 |
| 57 | Rifaximin (Xifaxan) | $310.0M | 111,328 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology